Anti-proliferative effects of paroxetine alone or in combination with sorafenib in HepG2 cells
Abstract Hepatocellular carcinoma (HCC) is a common cause of cancer-related death. Sorafenib is the first approved drug for the treatment of advanced HCC. Depression is frequent in cancer patients. Moreover, sorafenib might exert depression as an adverse drug reaction and paroxetine, a selective ser...
保存先:
| 主要な著者: | , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Universidade de São Paulo, Faculdade de Ciências Farmacêuticas
2023-01-01
|
| シリーズ: | Brazilian Journal of Pharmaceutical Sciences |
| 主題: | |
| オンライン･アクセス: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502022000100833&tlng=en |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|